Stock Price Movement, Grants for Projects, and Clinical Data Presentations - Research Report on Gilead, Bristol-Myers Squibb, HCA, Allergan, and Alexion Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, November 20, 2013 NEW YORK, November 20, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Gilead Sciences, Inc. (NASDAQ: GILD), Bristol-Myers Squibb Co. (NYSE: BMY), HCA Holdings Inc. (NYSE: HCA), Allergan, Inc. (NYSE: AGN), and Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Gilead Sciences, Inc. Research Report On November 15, 2013, Gilead Sciences Inc.'s (Gilead) stock rose 1.32%, ending the day at $69.89. Over the previous three trading sessions, shares of Gilead gained 3.37% compared to the Nasdaq Composite which gained 1.68% during the same period. The Full Research Report on Gilead Sciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/9898_GILD -- Bristol-Myers Squibb Co. Research Report On November 14, 2013, The Bristol Myers Squibb Foundation, the philanthropic arm of Bristol-Myers Squibb Co. (Bristol-Myers Squibb), marked World Diabetes Day and the third anniversary of its Together on Diabetes initiative by awarding four three-year, $450,000 grants for the following projects in the United States: Health Choice Network of Florida for the integration of behavioral sciences and care navigation into diabetes care of high-risk patients diagnosed with diabetes and depression; The University of Michigan for the evaluation and comparison of the effectiveness of diabetes self-management and psychosocial support offered at African American churches in Detroit through either a parish peer leader or a parish nurse against those approaches confined to diabetes self-management education alone; The University of Colorado for the development and implementation of a program to enhance the ability of Federally Qualified Health Centers and primary care practices in the Denver area to provide coordinated, patient-centered care for patients with diabetes and additional mental and behavioral health needs through both clinic- and community-based services; and East Carolina University for the design and evaluation of a collaborative, stepped care and "treat to target" intervention for patients in rural eastern North Carolina who have both uncontrolled type 2 diabetes and comorbid distress and/or depression. The Full Research Report on Bristol-Myers Squibb Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/81a9_BMY -- HCA Holdings Inc. Research Report On November 12, 2013, HCA Holdings Inc. (HCA) announced the appointment of Robert F. Carrel as President of HCA's Richmond, Virginia-based Capital Division, effective January 1, 2014. The Company informed that Carrel, who has been serving as Chief Financial Officer of the Capital Division since 2006, will succeed Margaret Lewis, who will be retiring. According to the Company, Carrel will have responsibility for 17 hospitals in Virginia, New Hampshire, Kentucky, and Indiana as Capital Division President. Further, HCA informed that it is conducting a search for a new Capital Division Chief Financial Officer. The Full Research Report on HCA Holdings Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/be59_HCA -- Allergan, Inc. Research Report On November 15, 2013, Allergan, Inc.'s (Allergan) stock rose 1.05%, ending the day at $96.41. Over the previous three trading sessions, shares of Allergan rose 5.14%, compared to the S&P 500 which gained 1.72% during the same period. The Full Research Report on Allergan, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/182a_AGN -- Alexion Pharmaceuticals, Inc. Research Report On November 9, 2013, Alexion Pharmaceuticals, Inc. (Alexion) announced that researchers presented data from four clinical trials, at Kidney Week 2013, the annual meeting of the American Society of Nephrology (ASN) in Atlanta, all demonstrating the clinical benefits of Soliris (eculizumab) for the treatment of atypical hemolytic uremic syndrome (aHUS), a genetic, chronic, ultra-rare disease associated with vital organ failure and premature death. According to Alexion, in two large, prospective, multinational studies, Soliris inhibited systemic complement-mediated thrombotic microangiopathy (TMA, the formation of blood clots in small blood vessels throughout the body) and improved renal function in both pediatric and adult patients with aHUS. Further, Alexion informed that the ASN meeting featured the presentation of three-year update data from two pivotal Phase 2 extension studies, which highlighted the long-term benefits of Soliris therapy in patients with aHUS. Alexion informed that in these studies, ongoing Soliris treatment at the three-year update was associated with sustained inhibition of complement-mediated TMA, as indicated by stabilization or continued improvement in key hematologic and renal endpoints, and quality of life. The Full Research Report on Alexion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/4619_ALXN ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AnalystsCorner.com SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Stock Price Movement, Grants for Projects, and Clinical Data Presentations - Research Report on Gilead, Bristol-Myers Squibb,
Press spacebar to pause and continue. Press esc to stop.